Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Eficacia preliminar de la terapia ocupacional que integra caballos en la autorregulación en jóvenes con autismo

30 de septiembre de 2026 actualizado por: Colorado State University

Eficacia preliminar de la terapia ocupacional que integra caballos en la autorregulación en jóvenes con trastorno del espectro autista

The goal of this clinical trial is to learn about occupational therapy integrating horses for autistic youth. The main questions it aims to answer are:

  • Does occupational therapy integrating horses improve self-regulation in autistic youth
  • Does occupational therapy integrating horses affect salivary cortisol and alpha-amylase

Participants will receive 10 weeks of occupational therapy, and will be asked to provide saliva samples each week.

Researchers will compare occupational therapy integrating horses to occupational therapy in a clinic to see if integrating horses affects self-regulation.

Descripción general del estudio

Estado

Terminado

Descripción detallada

The goal of this project is to quantify the unique benefits of integrating horses in occupational therapy compared to occupational therapy in a clinic (i.e., OTEE HORS vs. OT Clinic) for improving self-regulation in youth with ASD.

To address both aims we will randomize 64 youth with ASD ages 6-11 years old to OTEE HORS or OT clinic.

Specific Aim 1: Examine the preliminary efficacy of OTEE HORS compared to OT Clinic on self-regulation. Hypotheses: The OTEE HORS group will demonstrate significantly larger improvements than the OT Clinic group in five domains of self-regulation (hyperactivity [primary], irritability, emotional reactivity, dysphoria, and individual goal attainment).

Specific Aim 2: Identify potential physiological mechanisms that explain how integration of horses in occupational therapy impacts self-regulation in youth with ASD. Hypotheses 2A & B: The OTEE HORS group will demonstrate significantly larger decreases in salivary cortisol after each 60-minute therapy session and after the 10-week treatment course in comparison to the OT Clinic group. Hypotheses 2C & 2D: The OTEE HORS group will demonstrate significantly greater increases in salivary alpha-amylase after each 60-minute therapy session, and significantly greater decreases in salivary alpha-amylase over time as measured after the 10-week treatment course in comparison to the OT Clinic group. Exploratory Hypothesis 2E: Changes in physiological measures will significantly correlate with changes in Aim 1 behavioral measures.

Tipo de estudio

Intervencionista

Inscripción (Actual)

72

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Colorado
      • Denver, Colorado, Estados Unidos, 80216
        • Temple Grandin Equine Center

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

6 años a 11 años (Niño)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • meet clinical cut-offs for ASD on the Autism Diagnostic Observation Schedule, Second Edition(ADOS-2) and Social Communication Questionnaire (≥ 11)
  • nonverbal IQ≥65 on Leiter International Performance Scale Third Edition (Leiter-3)
  • verbally fluent defined by meeting standard administration criteria for ADOS-2 module 3
  • score >10 on the irritability subscale of the aberrant behavior checklist
  • able to tolerate a helmet and ride a horse for 10 minutes while following safety rules
  • and able to provide a saliva sample

Exclusion Criteria:

  • weigh more than 200 pounds
  • smoke or regularly use steroids
  • receive outpatient occupational therapy
  • have 10+ hours horseback riding experience in the previous 6 months
  • history of animal abuse or phobia of horses
  • have a sibling previously enrolled in the study

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Occupational Therapy Integrating Horses

10 weeks of occupational therapy focused on self-regulation skills, provided while participants are riding horses

10 weeks of occupational therapy focused on teaching and practicing self-regulation skills, provided while participants are riding horses

Comparador activo: Occupational Therapy in a Clinic

10 weeks of occupational therapy focused on self-regulation skills, provided in a traditional clinic environment

10 weeks of occupational therapy focused on teaching and practicing self-regulation skills, provided in a traditional clinic

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Hyperactivity
Periodo de tiempo: Week 1 & Week 10

The Hyperactivity subscale of the Aberrant Behavior Checklist, Second Edition (ABC-2) measures parent/caregiver-reported hyperactive and impulsive behaviors, including excessive activity, impulsivity, and difficulty remaining still or attending. The subscale consists of 16 items, with total scores ranging from 0-48. Higher scores indicate greater hyperactivity and more severe behavioral difficulties, while lower scores indicate less hyperactivity and better behavioral functioning. Item scores are summed to produce the subscale score.

Week 1 & Week 10

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Irritability
Periodo de tiempo: Week 1 & Week 10

The Irritability subscale of the Aberrant Behavior Checklist, Second Edition (ABC-2) measures behaviors associated with irritability, including aggression, self-injury, tantrums, and mood instability. The subscale consists of 15 items, with total scores ranging from 0-45. Higher scores indicate greater irritability and more severe behavioral difficulties, while lower scores indicate less irritability and better behavioral functioning. Items are rated based on the presence and severity of behaviors, and item scores are summed to produce the subscale score.

Week 1 & Week 10
Change in Emotional Reactivity
Periodo de tiempo: Week 1 & Week 10

The Emotional Reactivity subscale of the Emotion Dysregulation Inventory (EDI) measures the tendency to experience intense, rapidly escalating, and prolonged negative emotional responses. T-scores are standardized scores derived from the raw Emotional Reactivity score and have a mean of 50 and standard deviation of 10 in the normative sample. Higher T-scores indicate greater emotional reactivity and more severe emotion dysregulation, while lower T-scores indicate less emotional reactivity and better emotional regulation.

Week 1 & Week 10
Change in Dysphoria
Periodo de tiempo: Week 1 & Week 10

The Dysphoria subscale of the Emotion Dysregulation Inventory (EDI) measures symptoms of negative mood, including sadness, hopelessness, and emotional distress. T-scores are standardized scores derived from the raw Dysphoria score and have a mean of 50 and standard deviation of 10 in the normative sample. Higher T-scores indicate greater dysphoria and more severe negative mood symptoms, while lower T-scores indicate less dysphoria and better emotional well-being.

Week 1 & Week 10
Change in Concentration of Salivary Cortisol
Periodo de tiempo: Pre-session, Post-session, Post-session + 20 min, averaged across Intervention Weeks 2, 6 and 10

Change in Concentration of Salivary Cortisol from before-session, after-session, and 20 mins after-session. Saliva samples from Weeks 2, 6, and 10 at pre-session, post-session, and post-session +20, were assayed for cortisol content and included in the linear mixed model analyses.

Pre-session, Post-session, Post-session + 20 min, averaged across Intervention Weeks 2, 6 and 10
Change in Concentration of Salivary Alpha-amylase
Periodo de tiempo: Pre-session, Within-session, Post-session + 20 min, averaged across Intervention Weeks 2, 6 and 10

Change in concentration of salivary alpha-amylase from before-session, during-session, and 20 mins after-session. Saliva samples from Weeks 2, 6, and 10 at pre-session, within-session, and post-session +20, were assayed for alpha-amylase content and included in the linear mixed model analyses.

Pre-session, Within-session, Post-session + 20 min, averaged across Intervention Weeks 2, 6 and 10
Emotional Awareness Goal Attainment
Periodo de tiempo: Week 10

Attainment of individualized emotional awareness goal. Goal attainment scales range from -2 to +2 where higher values indicate greater progress towards individual goal, level 0 indicates goal was met.

Week 10
Self-regulation Tool Identification Goal Attainment
Periodo de tiempo: Week 10

Attainment of individualized goal related to identifying self-regulation tools. Goal attainment scales range from -2 to +2 where higher values indicate greater progress towards individual goal, level 0 indicates goal was met.

Week 10
Self-regulation Tool Use Goal Attainment
Periodo de tiempo: Week 10

Attainment of individualized goal related to using self-regulation tools. Goal attainment scales range from -2 to +2 where higher values indicate greater progress towards individual goal, level 0 indicates goal was met.

Week 10

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Brittany C Peters, PhD, Colorado State University

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

21 de marzo de 2023

Finalización primaria (Actual)

23 de abril de 2025

Finalización del estudio (Actual)

1 de noviembre de 2025

Fechas de registro del estudio

Enviado por primera vez

7 de abril de 2023

Primero enviado que cumplió con los criterios de control de calidad

26 de abril de 2023

Publicado por primera vez (Actual)

6 de mayo de 2023

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

2 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

30 de septiembre de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 4049
  • 1R21HD109957-01 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

De-identified data will be shared in an appropriate data repository, such as the "Data and Specimen Hub" (DASH) or the "National Database for Autism Research" (NDAR). Data will be shared no later than the acceptance for publication of the main findings from the final dataset. Salimetrics will discard saliva samples after testing, and therefore saliva samples will not be available for sharing.

Marco de tiempo para compartir IPD

We will share in an appropriate data repository indefinitely, no later than the acceptance for publication of the main findings from the final dataset

Tipo de información de apoyo para compartir IPD

  • CIF

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir